#venture-firm-strategy

#venture-firm-strategy

In the high-stakes world of regulated AI, your model is only as good as the person who built it. We are betting on a human-first approach to technology.

Curiosity is key for young engineers. Asking a lot of questions is a great way to build relationships within a company, according to James Everingham.

Yuzu Health has raised $35M in Series A funding, led by General Catalyst and Chemistry, with participation from Anthropic's Anthology Fund and others, totaling $40M in equity funding.

Eisen, an escheatment compliance platform that automates dormant account offboarding and unclaimed property reporting for regulated financial institutions, has raised $7.2M in funding according to a recent SEC filing.

Awards may be encouraging and occasionally useful for visibility, but they are weak indicators of validation and poor predictors of long-term success. In the longevity and healthspan industry, where timelines are long and claims are easy to overstate, venture capital ultimately follows alignment and evidence, not applause received at glitzy industry events.

Raising venture capital too early can cost you control, leverage and even your company. Early capital is often highly dilutive, selling off your future before your blueprint is complete. The difference between lighting a spark and burning your equity to ash is a lesson many founders learn too late.

ADIN uses AI to replace the human analysts involved in venture dealmaking. Put in a startup's pitch deck, and out comes a detailed analysis of its business model and founding team, a list of diligence questions and compliance risks, an estimate of the total addressable market, and a suggested valuation. ADIN has about a dozen different agentic investors, each with a distinct persona and investing thesis.

Because startups typically don't have a track record of success to attract potential clients, they can offer a trial of their platform for free or at a lower cost to showcase what their platform can do and how reliable it is. The enterprise - a potential client - can test the newest technologies without the worry of committing to a complete and often costly rollout.